431 results on '"De Pas T."'
Search Results
2. Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials
3. Clinical management of patients with thymic epithelial tumors: the recommendations endorsed by the Italian Association of Medical Oncology (AIOM)
4. Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: a systematic review and meta-analysis
5. 'Heterogeneity of treatment effect on patients' long-term outcome according to pathological response type in neoadjuvant RCTs for breast cancer.'
6. Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials
7. Genetic Alterations of Melanoma Brain Metastases: A Systematic Review and Meta-Analysis
8. Improved outcomes in women with BRAF-mutant melanoma treated with BRAF/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysis
9. Transcription regulators and ultra-rare and other rare translocation-related sarcomas treated with trabectedin: A proof of principle from a post-hoc analysis
10. Improved outcomes in women with BRAF-mutant melanoma treated with BRAF/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysis
11. Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study
12. Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial
13. Different Response to Immunotherapy According to Melanoma Histologic Subtype
14. A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors
15. Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)
16. Improved outcomes in women with BRAF-mutant melanoma treated with BRAF/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysis
17. Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials
18. EGFR-TKI plus anti-angiogenic drugs in EGFR-mutated non–small cell lung cancer: A meta-analysis of randomized clinical trials
19. Effectiveness of intensive clinical and radiological follow-up in patients with surgically resected NSCLC. Analysis of 2661 patients from the prospective MAGRIT trial
20. Different Response to Immunotherapy According to Melanoma Histologic Subtype
21. Association of Anticancer Immune Checkpoint Inhibitors with Patient-Reported Outcomes Assessed in Randomized Clinical Trials: A Systematic Review and Meta-Analysis
22. Endocrine-responsive lobular carcinoma of the breast: Features associated with risk of late distant recurrence
23. Thymic carcinoma with Lynch syndrome or microsatellite instability, a rare entity responsive to immunotherapy
24. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†
25. Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer
26. Phase I/II study of the tumour-targeting human monoclonal antibody–cytokine fusion protein L19-TNF in patients with advanced solid tumours
27. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis
28. Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations
29. Sex-based dimorphism of anticancer immune response and molecular mechanisms of immune evasion
30. Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate
31. Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer
32. The choice of whether to participate in a phase I clinical trial: increasing the awareness of patients with cancer. An exploratory study
33. Erratum to “Lung cancer” [Crit. Rev. Oncol./Hematol. 27 (February (2)) (1998) 133–134]
34. Sex-based differences of the tumor mutational burden and T-cell inflammation of the tumor microenvironment
35. Does Lung Cancer Screening with Low-Dose CT Remain Promising Despite Disappointing DANTE Results?
36. Gemcitabine and pemetrexed combination: the key role of the sequence of drugs administration
37. Differentiating neuroblastoma arising in mediastinal germ cell tumour
38. Life-threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy
39. 4 Oral - Improved outcomes in women with BRAF-mutant melanoma treated with BRAF/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysis
40. Reply to the article “Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity” by V. R. Rozados et al. (Ann Oncol 2004; 15: 1543–1550): … and in humans?
41. Sex-based differences of the Tumor mutational burden and T-cell inflammation of the tumor microenvironment
42. Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis
43. Reply to Jeffrey Graham, Omar Abdel-Rahman, Toni K. Choueiri, and Daniel Y.C. Heng's Letter to the Editor re: Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al. Cancer Immunotherapy Efficacy and Patients’ Sex: A Systematic Review and Meta-analysis. Lancet Oncol 2018;19:737–46: Outcomes of Metastatic Renal Cell Carcinoma by Gender: Contrasting Results from the International mRCC Database Consortium
44. CDX-2 should be included in the work-up of patients with lung metastases from unknown primary
45. Preoperative chemotherapy is essential for conservative surgery of Askin tumors
46. Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas
47. Gemcitabine-induced systemic capillary leak syndrome
48. Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer
49. Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer
50. Chemotherapy followed by three-times daily hyperfractionated accelerated radiotherapy in stage IIIa (pN2)/IIIb non-small cell lung cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.